Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net earnings	$ 3,627	$ 2,584
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	296	286
Amortization of intangible assets	279	307
Stock-based compensation	229	198
Upfront costs and milestones related to collaborations	280	574
Other, net	369	324
Changes in operating assets and liabilities, net of acquisitions:
Accounts and other receivables	(842)	95
Inventories	(446)	20
Prepaid expenses and other assets	452	(260)
Accounts payable and other liabilities	1,328	(1)
Cash flows from operating activities	5,572	4,127
Cash flows from investing activities
Acquisitions of Pharmacyclics, Inc., net of cash acquired	(11,488)
Other acquisitions and investments	(794)	(572)
Acquisitions of property and equipment	(387)	(459)
Transfer to restricted cash		(2,700)
Purchases of investment securities	(851)	(1,169)
Sales and maturities of investment securities	862	1,460
Other	19
Cash flows from investing activities	(12,639)	(3,440)
Cash flows from financing activities
Net change in short-term borrowings	335	(112)
Proceeds from issuance of long-term debt	16,660
Debt issuance cost	(179)	(82)
Dividends paid	(2,454)	(1,987)
Purchases of treasury stock	(6,342)	(352)
Proceeds from the exercise of stock options	123	164
Other, net	40	(42)
Cash flows from financing activities	8,183	(2,411)
Effect of exchange rate changes on cash and equivalents	(241)	(152)
Net increase (decrease) in cash and equivalents	875	(1,876)
Cash and equivalents, beginning of period	8,348	9,595
Cash and equivalents, end of period	9,223	$ 7,719
Supplemental Schedule of Non-Cash Investing and Financing Activities
Issuance of common stock associated with the acquisition of Pharmacyclics, Inc.	$ 8,405